Therefore, cancer immunotherapy intends to ameliorate immunosuppressive TME through breaking PD-1/PD-L1 interaction (by immune checkpoint inhibitors [ICIs]) and enhancing tumor-specific immune response (for example, via adoptive cell therapy [ACT]) [4]. Here, CD274 is linked to neoplasm.